Kazia Therapeutics shares are trading lower, after initally spiking higher, amid increased volatility in the stock after the company announced the early conclusion of the Phase 1 Paxalisib trial in solid tumors after reaching the primary endpoint.
Benzinga Newsdesk - Feb 21, 2024, 11:19AM